Summary
The U.S. Food and Drug Administration (FDA) has approved mFlusiva, the first mRNA-based influenza vaccine developed by Moderna, for individuals aged 50 and older. This new vaccine demonstrated up to 27% greater effectiveness than traditional flu shots in a study and offers advantages in rapid development and strain matching, marking a significant milestone in public health.